Celcuity Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celcuity Inc. on August 11, 2022, reporting events occurring on August 9, 2022. The filing primarily details the entry into a material definitive agreement to amend an existing loan facility and references the release of financial results for the second quarter ended June 30, 2022.
Key Financial Metrics and Debt Structure
The filing focuses on a significant expansion of the Company's debt facility rather than operational financial metrics like revenue or profit, which are referenced but not detailed in this text.
- Total Debt Capacity: Increased to $75 million in term loans, a $50 million increase from the original $25 million facility.
- Funding Status: The first term loan of $15.0 million was funded on April 8, 2021. Remaining tranches are contingent on specific milestones.
- Interest Rate: Prime rate or 3.25% (whichever is greater) plus 5.70%. The Company elected to pay 4.95% of the interest rate in-kind (PIK), accruing as principal.
- Maturity: April 8, 2027.
- Collateral: Secured by all assets of the Company.
- Conversion Rights: Lender (Innovatus) may convert up to $6.6 million of principal into common stock at $10.00 per share until August 9, 2025.
Material Changes and Milestone Triggers
The amendment introduces a milestone-based drawdown structure for the remaining $60 million in potential funding:
- Second Tranche ($20M): Eligible upon closing of the $100 million private placement announced May 16, 2022. Deadline to request: December 31, 2022.
- Third Tranche ($10M): Eligible upon achieving 50% enrollment in VIKTORIA-1 Study 1 Arm A and Arm C. Window: September 1, 2023, to April 1, 2024.
- Fourth Tranche ($20M): Eligible upon reporting statistically significant improvement in Progression-Free Survival (PFS) for Study 1 Arm A or B relative to Arm C. Window: August 1, 2024, to November 1, 2024.
- Fifth Tranche ($10M): Eligible upon submission of a New Drug Application (NDA) to the FDA for gedatolisib. Window: November 1, 2024, to February 28, 2025.
Outlook, Risks, and Contingencies
Repayment Terms: The Company is entitled to interest-only payments until May 1, 2025 (potentially extendable to May 1, 2026). Prepayment is permitted after August 9, 2023, with tiered fees (0.00% - 1.00%). A 3.0% prepayment fee applies if a change of control or default occurs before the first anniversary of the amendment.
Fees: A final fee of 4.5% of funded amounts not converted to equity applies if prepayment, default, or change of control occurs before August 9, 2025.
Risks: The loans are subject to customary events of default which could trigger immediate acceleration. The agreement includes financial covenants related to liquidity, trailing twelve-month revenue, and funded loan amounts. The filing notes that Q2 2022 financial results were released on August 11, 2022, but specific figures are not contained in this 8-K text.
Investor Verification Checklist
- Verify the closing status of the $100 million private placement to confirm eligibility for the $20 million second tranche.
- Review the August 11, 2022 press release (Exhibit 99.1) for specific Q2 2022 revenue, cash burn, and liquidity figures.
- Monitor clinical trial enrollment rates for the VIKTORIA-1 study to assess the likelihood of drawing the third tranche.
- Confirm the current cash balance against the interest-only payment schedule and PIK accruals.
- Review the full text of the Amended Loan Agreement (Exhibit 10.1) for specific definitions of financial covenants and events of default.